<DOC>
	<DOC>NCT00765492</DOC>
	<brief_summary>This is a study to evaluate safety, tolerability, PK and PD effects of orally administered AZD8529 after multiple ascending doses</brief_summary>
	<brief_title>AZD8529 Multiple Ascending Dose Study in Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Female subjects must be of nonchild bearing potential. Has received another new chemical entity (defined as a compound which has not been approved for marketing) or has participated in any other clinical study that included drug treatment within 30months of the first administration of investigational prod Plasma donation within one month of screening or any blood donation/blood loss &gt; 500mL during the 3 months prior to screening Clinically relevant abnormalities in physical examinations, vital signs, ECG, clinical chemistry, hematology or urinalysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Phase I</keyword>
</DOC>